December 18, 2018 04:28 PM EST

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug

John Carroll

Editor & Founder

Surface Oncology’s lead drug — an anti-CD47 antibody — has run into some heavy turbulence, and the Cambridge, MA-based biotech is buckling up for a rough ride …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

‘Just the beginning’: Nobel Prizes show the AI era has arrived in biotech

Exclusive Q&A: FDA's principal deputy commissioner on taking over for Califf, adcomms, accelerated approvals and more

AI biotech insitro partners with Lilly on metabolic disease drugs

Zealand Pharma hit with second CRL for glucagon receptor agonist

CMS looks to $2 out-of-pocket cap for some commonly used generic drugs

Crinetics’ $500M offering; Boehringer inks deal with macrocycles biotech

Sur­face On­col­o­gy reins back its lead pro­gram af­ter track­ing low-dose tox­i­c­i­ty for CD47 drug

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug